Abstract

(1) Tomentosin is the most representative sesquiterpene lactone extracted by I. viscosa. Recently, it has gained particular attention in therapeutic oncologic fields due to its anti-tumor properties. (2) In this study, the potential anticancer features of tomentosin were evaluated on human Burkitt’s lymphoma (BL) cell line, treated with increasing tomentosin concentration for cytotoxicity screening. (3) Our data showed that both cell cycle arrest and cell apoptosis induction are responsible of the antiproliferative effects of tomentosin and may end in the inhibition of BL cell viability. Moreover, a microarray gene expression profile was performed to assess differentially expressed genes contributing to tomentosin activity. Seventy-five genes deregulated by tomentosin have been identified. Downregulated genes are enriched in immune-system pathways, and PI3K/AKT and JAK/STAT pathways which favor proliferation and growth processes. Importantly, different deregulated genes identified in tomentosin-treated BL cells are prevalent in molecular pathways known to lead to cellular death, specifically by apoptosis. Tomentosin-treatment in BL cells induces the downregulation of antiapoptotic genes such as BCL2A1 and CDKN1A and upregulation of the proapoptotic PMAIP1 gene. (4) Overall, our results suggest that tomentosin could be taken into consideration as a potential natural product with limited toxicity and relevant anti-tumoral activity in the therapeutic options available to BL patients.

Highlights

  • IntroductionBurkitt’s lymphoma is a highly aggressive B cell non-Hodgkin lymphoma (NHL), which originates from mature germinal or post germinal center B cells

  • To evaluate whether tomentosin could decrease the survival of human Burkitt’s lymphoma (BL) cells, we treated human BL and MRC5 cell lines with increasing concentrations of the drug

  • We focused on investigating if tomentosin, the most representative natural potent bioactive compound extracted from the I. viscosa plant, might be responsible for the bioactivity of I. viscosa extract in the same tumor

Read more

Summary

Introduction

Burkitt’s lymphoma is a highly aggressive B cell non-Hodgkin lymphoma (NHL), which originates from mature germinal or post germinal center B cells. (q24;q32) and its variants, t(2;8) (p12;q24.1) and t(8;22) (q24.1;q11.2), involving c-MYC oncogene. The constitutive activation of the c-MYC is followed by the abnormal transcriptional regulation of downstream genes, resulting in cellular transformation, inhibition of cell cycle checkpoints, and resistance to apoptosis [1,2]. Generation sequencing analysis has identified numerous somatic mutations in patients with BL, with the highest frequency for transcription factor TCF3 or its negative regulator ID3 [3]. BL accounts for less than 5% of lymphomas in adults.

Objectives
Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call